Seribantumab

Generic Name
Seribantumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1334296-12-6
Unique Ingredient Identifier
1N3L70MDFX
Background

Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

Phase 2
Completed
Conditions
Metastatic Pancreatic Cancer
Interventions
Drug: Seribantumab
First Posted Date
2021-03-10
Last Posted Date
2022-01-12
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
1
Registration Number
NCT04790695
Locations
🇨🇦

The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

First Posted Date
2020-05-12
Last Posted Date
2023-08-08
Lead Sponsor
Elevation Oncology
Target Recruit Count
75
Registration Number
NCT04383210
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 39 locations

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

First Posted Date
2017-08-08
Last Posted Date
2020-09-02
Lead Sponsor
Elevation Oncology
Target Recruit Count
22
Registration Number
NCT03241810
Locations
🇺🇸

Stamford Hospital, Stamford, Connecticut, United States

🇺🇸

University of Mississippi, Jackson, Mississippi, United States

🇺🇸

University of Utah Health Care - Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 56 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy